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Treatment reduction for children and young adults with 
low-risk acute lymphoblastic leukaemia deﬁ ned by minimal 
residual disease (UKALL 2003): a randomised controlled trial
Ajay Vora, Nick Goulden, Rachel Wade, Chris Mitchell, Jeremy Hancock, Rachael Hough, Clare Rowntree, Sue Richards
Summary
Background Minimal residual disease (MRD) is the most sensitive and speciﬁ c predictor of relapse risk in children 
with acute lymphoblastic leukaemia (ALL) during remission. We assessed whether treatment intensity could be 
adjusted for children and young adults according to MRD risk stratiﬁ cation.
Methods Between Oct 1, 2003 and June 30, 2011, consecutive children and young adults (aged 1–24 years) with ALL 
from the UK and Ireland were recruited. Eligible patients were categorised into clinical standard, intermediate, and 
high risk groups on the basis of a combination of National Cancer Institute (NCI) criteria, cytogenetics, and early 
response to induction therapy, which was assessed by bone marrow blast counts taken at days 8 (NCI high-risk patients) 
and 15 (NCI standard-risk patients) after induction began. Clinical standard-risk and intermediate-risk patients were 
assessed for MRD. Those classiﬁ ed as MRD low risk (undetectable MRD at the end of induction [day 29] or detectable 
MRD [less than 0·01%] at day 29 that became undetectable by week 11) were randomly assigned to receive one or two 
delayed intensiﬁ cation courses. Patients had received induction, consolidation, and interim maintenance therapy 
before they began delayed intensiﬁ cation. Delayed intensiﬁ cation consisted of pegylated asparaginase on day 4; 
vincristine, dexamethasone (alternate weeks), and doxorubicin for 3 weeks; and 4 weeks of cyclophosphamide and 
cytarabine. Computer randomisation was done with stratiﬁ cation by MRD result and balancing for sex, age, and white 
blood cell count at diagnosis by method of minimisation. Patients, clinicians, and data analysts were not masked to 
treatment allocation. The primary outcome was event-free survival (EFS), which was deﬁ ned as time to relapse, 
secondary tumour, or death. Our aim was to rule out a 7% reduction in EFS in the group given one delayed 
intensiﬁ cation course relative to that given two delayed intensiﬁ cation courses. Analyses were by intention to treat. 
This trial is registered, number ISRCTN07355119.
Findings Of 3207 patients registered in the trial overall, 521 MRD low-risk patients were randomly assigned to receive 
one (n=260) or two (n=261) delayed intensiﬁ cation courses. Median follow-up of these patients was 57 months 
(IQR 42–72). We recorded no signiﬁ cant diﬀ erence in EFS between the group given one delayed intensiﬁ cation 
(94·4% at 5 years, 95% CI 91·1–97·7) and that given two delayed intensiﬁ cations (95·5%, 92·8–98·2; unadjusted 
odds ratio 1·00, 95% CI 0·43–2·31; two-sided p=0·99). The diﬀ erence in 5-year EFS between the two groups was 
1·1% (95% CI –5·6 to 2·5). 11 patients (actuarial relapse at 5 years 5·6%, 95% CI 2·3–8·9) given one delayed 
intensiﬁ cation and six (2·4%, 0·2–4·6) given two delayed intensiﬁ cations relapsed (p=0·23). Three patients (1·2%, 
0–2·6) given two delayed intensiﬁ cations died of treatment-related causes compared with none in the group given 
one delayed intensiﬁ cation (p=0·08). We recorded no signiﬁ cant diﬀ erence between groups for serious adverse events 
and grade 3 or 4 toxic eﬀ ects; however, the second delayed intensiﬁ cation course was associated with one (<1%) 
treatment-related death, and 74 episodes of grade 3 or 4 toxic eﬀ ects in 45 patients (17%).
Interpretation Treatment reduction is feasible for children and young adults with ALL who are predicted to have a low 
risk of relapse on the basis of rapid clearance of MRD by the end of induction therapy.
Funding Medical Research Council and Leukaemia and Lymphoma Research.
Introduction
Several step changes in outcomes for children with acute 
lymphoblastic leukaemia (ALL) were made in the last 
three decades of the 20th century; at the start of the 
21st century, 80% of patients could expect to survive 
without relapse after ﬁ rst-line treatment.1–4 The challenges 
for clinical trials at that time were to sustain that rate of 
improvement without new drugs and to address the 
problem of immediate and long-term toxic eﬀ ects of 
treatment. 
Historically, the intensity of treatment received by a 
patient with ALL was based on risk of relapse, which was 
predicted by a combination of clinical, cytogenetic, and 
morphological early response criteria.1,3,4 However, risk 
groups identiﬁ ed by these variables are fairly non-speciﬁ c, 
because most relapses arise in medium-risk and low-risk 
groups.1,3,4 Monitoring of minimal residual disease (MRD) 
has been shown to be the most sensitive and speciﬁ c 
predictor of relapse risk in several large studies.5,6 These 
studies established that the positive and negative predictive 
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value of a speciﬁ c MRD result depends on the sensitivity of 
the technique used to measure it, the point at which it is 
measured, and the treatment received by the patient before 
and after the point of assessment. Despite diﬀ erences in 
these variables in published studies,5,6 the signiﬁ cance of 
results relating to speciﬁ c clinical endpoints is consistent. 
Patients who have undetectable MRD by the end of 
induction therapy have a negligible risk of relapse, whereas 
those who have more than 0·01% MRD at that timepoint 
have a relapse risk of more than 20%. Hence, MRD 
monitoring has been used in several clinical trials1,7–9 to 
better predict the risk of relapse for an individual.
We tested whether adjustment of treatment intensity 
according to MRD risk stratiﬁ cation was feasible. We 
report the outcome for patients in the trial overall and the 
results of treatment reduction for MRD low-risk patients.
Methods 
Study design and participants 
From Oct 1, 2003, to June 30, 2011, we recruited 
consecutive children and young adults with ALL 
diagnosed at 45 centres in the UK and Ireland into the 
Medical Research Council UK ALL 2003 (MRC UKALL 
2003) randomised controlled trial. ALL was diagnosed 
with standard morphological and ﬂ ow cytometric criteria 
as previously described.10 Patients aged younger than 
1 year or with mature B-cell ALL were not eligible. 
Patients with Philadelphia-chromosome-positive ALL 
were transferred to other protocols such as the European 
Study for Philadelphia-chromosome-positive ALL 
(EsPhALL)11 or UKALL XII12 once their Philadelphia-
chromosome status was known. 
The upper age limit of entry was 18 years at the start of 
the trial, but was increased to 20 years in February, 2006, 
and to 24 years from August, 2007, because retrospective 
studies showed that young adults obtained an improved 
outcome when treated with paediatric protocols. The 
overall treatment intensity for patients with Down’s 
syndrome had to be reduced after June, 2008, because of 
excess treatment-related mortality; from that time, patients 
with Down’s syndrome were registered on the trial but did 
not undergo randomisation and were treated as clinical 
standard-risk patients, with adjustment of postinduction 
treatment according to response to induction therapy.
Patients were stratiﬁ ed according to initial clinical risk of 
relapse, on the basis of three metrics: the National Cancer 
Institute (NCI) risk criteria (NCI standard risk: patients 
younger than 10 years with a white blood cell count of less 
than 50×10⁹ per L; NCI high risk: patients aged 10 years or 
older and those with a white blood cell count of at least 
50×10⁹ per L), leukaemia cytogenetics (all patients with a 
cytogenetic abnormality involving rearrangement of the 
MLL gene, hypodiploidy [<45 chromosomes], or 
intrachromosomal ampliﬁ cation of chromosome 21 were 
classiﬁ ed as clinical high risk), and early response to 
induction therapy as assessed by bone-marrow morphology 
on day 8 and 15 of treatment in patients younger than 
16 years.  Patients who had more than 25% of the marrow 
made up of blast cells at day 8 (NCI high risk) or 15 (NCI 
standard risk) were reclassiﬁ ed to the clinical high risk 
group irrespective of initial classiﬁ cation and were not 
eligible for MRD stratiﬁ cation and randomisation. NCI 
standard-risk patients had to have an early response of less 
than 25% marrow blasts at the day 15 assessment 
(reclassiﬁ ed as clinical standard risk) and NCI high-risk 
patients who had less than 25% marrow blasts at day 8 
were reclassiﬁ ed as clinical intermediate risk to be eligible 
for randomisation. All patients who were 16 years or older 
were treated as clinical intermediate risk irrespective of 
day 8 or 15 bone-marrow response and were eligible for 
MRD stratiﬁ cation and randomisation.
We stratiﬁ ed clinical standard and intermediate risk 
groups by bone-marrow MRD at the end of induction and 
recovery from consolidation (before start of interim 
maintenance). Clinical high-risk patients were not eligible 
for MRD stratiﬁ cation. MRD was measured by a 
standardised real-time quantitative PCR method for 
immunoglobulin and T-cell receptor antigen gene 
rearrangements. The quantitative range of the assay was 
10–⁴, which was done within four laboratories in the UK 
that participated in a European quality-assurance 
scheme.13,14 All MRD results were centrally reviewed. 
Patients with undetectable MRD after induction (day 29) 
and before interim maintenance were classiﬁ ed as MRD 
low risk, as were those with detectable (less than 0·01%) 
MRD at the end of induction but undetectable MRD before 
the start of interim maintenance. Those with at least 
0·01% MRD at the end of induction were classiﬁ ed as 
MRD high risk. Patients in whom MRD could not be 
measured because no or poor-quality samples were 
available and those with persistent disease which was less 
than 0·01% MRD before the start of interim maintenance 
were classiﬁ ed as MRD indeterminate. 
The protocol was approved by the Scottish Multi-Centre 
Research Ethics Committee. Patients were enrolled at 
individual treatment centres by principal investigators 
after written informed consent from carers or patients 
was obtained. The trial was monitored by an independent 
data monitoring committee, which reviewed safety and 
eﬃ  cacy data annually.
Randomisation and masking 
MRD low-risk patients were randomly assigned (1:1) to 
receive one (reduced treatment) or two (standard 
treatment) delayed intensiﬁ cations and MRD high-risk 
patients were randomly assigned (1:1) to standard 
treatment or an intensive schedule. Treatment allocation 
in both groups was obtained by telephone call to the 
central trials unit, where computer randomisation was 
done, with stratiﬁ cation by MRD result and balancing for 
sex, age (<10 years vs ≥10 years) and white blood cell count 
at diagnosis (<50 × 10⁹ per L vs ≥50 × 10⁹ per L) by method 
of minimisation. Patients, clinicians, and data analysts 
were not masked to treatment allocation.
For trial protocol see http://
www.ctsu.ox.ac.uk/research/
mega-trials/leukaemia-trials/
ukall-2003
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Procedures 
Patients received one of three escalating-intensity 
treatment regimens depending on their clinical risk 
grouping (ﬁ gure 1; full regimen details are provided in 
the appendix). NCI standard-risk patients received a 
three-drug induction of vincristine, steroids, and 
asparaginase for 4 weeks. NCI high-risk patients also 
received daunorubicin during induction. All patients 
received two doses of intrathecal methotrexate in 
induction, and those who had blasts in their 
cerebrospinal ﬂ uid at diagnosis received an additional 
two doses at day 15 and 21.
During consolidation, clinical standard-risk patients 
received daily oral mercaptopurine and four doses of weekly 
intrathecal methotrexate. Clinical intermediate-risk patients 
also had 4 weeks of cyclo phosphamide and cytarabine 
(Berlin–Frankfurt–Munster [BFM] consolidation). Clinical 
high-risk patients received an additional four doses of 
vincristine and two doses of pegylated asparaginase during 
the BFM consolidation course.
Clinical standard-risk and intermediate-risk patients 
received the same interim maintenance courses for 
8 weeks: daily oral mercaptopurine and weekly methotrexate 
with monthly vincristine and steroid pulses. Clinical high-
risk patients received escalating doses of intravenous 
methotrexate without folinic acid rescue, and vincristine 
and pegylated asparaginase as interim maintenance.
Clinical standard-risk and inter mediate-risk patients 
assigned to standard treatment received two delayed 
intensiﬁ cation courses separated by interim maintenance 
courses (ﬁ gure 1), and those assigned to reduced treatment 
received only one delayed intensiﬁ cation course followed 
by continuing therapy. Clinical standard-risk and 
intermediate-risk patients received the same delayed 
intensiﬁ cation courses: one dose of pegylated asparaginase 
on day 4; vincristine, dexamethasone (alternate weeks), 
and doxorubicin for 3 weeks; and then 4 weeks of 
cyclophosphamide and cytarabine as during the BFM 
consolidation course. Clinical high-risk patients received 
the same course but with the addition of two doses of 
vincristine and one dose of pegylated asparaginase. 
For continuing therapy, all patients received oral 
mercaptopurine and methotrexate, monthly vincristine 
and steroid pulses, and intrathecal methotrexate every 
3 months. Male patients received treatment for 3 years 
and female patients for 2 years from the start of interim 
maintenance.
All patients received 6 mg/m² oral dexamethasone 
daily during induction and maintenance courses, with a 
maximum dose of 10 mg. We could not establish the 
proportion of patients in whom the dose was capped, 
because data were not obtained centrally. In delayed 
intensiﬁ cation courses, all patients received 10 mg/m² 
daily dexamethasone (without a cap) for 2 weeks on 
alternate weeks. 
All patients received pegylated asparaginase (Oncosopar; 
Gaithersburg, MD, USA; Medac GmBH; 1000 units/m² 
per dose given intramuscularly) throughout treatment. 
Clinical standard-risk and intermediate-risk patients 
received four doses (two in induction and one in each 
delayed intensiﬁ cation course). Clinical high-risk patients 
received 12 doses (two in induction, two in each interim 
Standard-risk patients
Induction CNS-directed therapy + IM1 DI1 IM2 DI2 Continuing therapy
Female patients to week 112
Male patients to week 164
Intermediate-risk patients
Induction BFM consolidation
+ CNS-directed 
therapy
DI1
DI1
IM1
Capizzi IM1
IM2 DI2 Continuing therapy
Female patients to week 112
Male patients to week 164
High-risk patients
Induction BFM consolidation
+ CNS-directed 
therapy
IM2 DI2 Continuing therapy
Female patients to week 117
Male patients to week 169
0 4 5 16 17 23 24 31 383932
0 9 10 17 18 24 25 32 39 40335
0 13 14 21 22 29 30 37 45 46385
Time (weeks)
Figure 1: Outline of treatment regimens for clinical risk groups deﬁ ned by National Cancer Institute criteria, cytogenetics, and early response
IM=interim maintenance. DI=delayed intensiﬁ cation. BFM=Berlin–Frankfurt–Munster. MRD=minimal residual disease. MRD low-risk patients assigned to one delayed 
intensiﬁ cation receive DI1 and then receive continuing therapy. MRD high-risk patients assigned to the intensive schedule transferred to clinical high-risk regimen 
after induction.
See Online for appendix
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maintenance course, and three in each delayed 
intensiﬁ cation course).
Patients with ﬁ ve leucocytes per μL or more and blasts 
in a diagnostic sample of cerebrospinal ﬂ uid with fewer 
than ten red blood cells per μL received an extra two 
doses of intrathecal methotrexate in induction and 24 Gy 
cranial radiotherapy during consolidation until August, 
2009, after which point they received only the additional 
doses of intrathecal methotrexate during induction. 
Patients with traumatic lumbar puncture and blasts in 
the cerebrospinal ﬂ uid, and those with fewer than ﬁ ve 
blasts per μL also received an extra two doses of 
intrathecal methotrexate during induction. Clinical high-
risk patients received Capizzi intravenous methotrexate 
at doses of less than 500 mg/m² without folinic acid 
rescue during interim maintenance.
Patients whose bone marrow consisted of more than 
25% blasts at day 29 of induction, or those with a 
high-risk karyotype whose bone marrow consisted of 
more than 5% blasts at that timepoint were eligible for 
allogeneic haemopoietic stem-cell transplantation in 
the ﬁ rst complete remission. Additionally, patients with 
an intrachromosomal ampliﬁ cation of chromosome 21 
and a morphological slow early response at day 8 or 15, 
or MRD high-risk status at day 29 were eligible for 
allogeneic transplant in ﬁ rst complete remission. 
Statistical analysis
We anticipated that total accrual to the trial in a 6-year 
period would be 2500 patients, of whom we expected 
about 400 to be eligible for the randomisation of the 
MRD low-risk group. The primary outcome measure 
was event-free survival (EFS). EFS was deﬁ ned as time 
to relapse, secondary tumour, or death. The secondary 
outcome measures were cumulative risk of relapse, 
treatment-related toxic eﬀ ects, and overall survival. In 
view of the few relapses expected in this group, and 
with a one-sided p value, we would have 80% power to 
detect a reduction in 5-year EFS in the group given one 
delayed intensiﬁ cation course from 95% to 88%. The 
chosen size of diﬀ erence was pragmatic and was based 
on probable accrual to the trial and randomisation 
refusals. 
However, the proportion of patients in the low-risk 
group was higher than had been originally anticipated 
and, because of a shortfall in recruitment to the high-risk 
group, the trial was kept open after its original closing date 
of Oct 31, 2009. Therefore, the data monitoring committee 
recommended an increase in sample size in the low-risk 
group to narrow the conﬁ dence intervals of the diﬀ erences 
in outcome between groups. Randomisation of MRD low-
risk patients ended on Aug 24, 2009, and randomisation of 
MRD high-risk patients on June 30, 2011, after the target 
number of patients had been recruited.
We compared categorical variables with standard χ² tests. 
We examined the relation between sex, age, white blood 
cell count, and immunophenotype, and between those 
variables and MRD risk group with logistic regression. For 
time-to-event outcomes, we produced Kaplan-Meier curves 
and compared them with the log-rank method. We counted 
only ﬁ rst events, censoring at competing events—eg, time 
to bone-marrow relapse included censoring at non-bone 
marrow relapse or death in remission for patients with 
these events as their ﬁ rst. Patients who died within 35 days 
of starting treatment or who never achieved remission, or 
both, were deemed to be induction failures. They 
were included in analyses of EFS and overall survival, but 
excluded from analyses of relapse or remission death. 
We calculated hazard ratios and 95% CIs as 
exp[(O – E)/V +/– 1·96/√V], in which O=observed events, 
E=expected events, and V=variance.15 We calculated a CI 
for the diﬀ erence in 5-year EFS for the MRD low-risk 
group on the basis of the fact that the odds ratio can be 
estimated by the logarithm of the survival in the 
reduced-treatment group divided by the logarithm of 
the survival in the standard group. We used Cox 
820 indeterminate 
         MRD status
808 high-risk MRD† 1059 low-risk MRD 34 died within 35 days
       or never remitted
261 assigned to two delayed 
         intensiﬁcations‡
215 not randomly assigned
         97 refused
         7 had Down’s syndrome
         4 because of toxic eﬀects
      28 other reason
      79 unknown
521 randomly assigned
260 assigned to one delayed 
          intensiﬁcation‡
3207 patients registered in the trial
3126 eligible for analysis
81 excluded
       3 had been registered twice
       7 withdrew consent
     12 had been misdiagnosed*
    59 Philadelphia-chromosome-
           positive
  989 clinical intermediate risk1732 clinical standard risk 405 clinical high risk 
2721 eligible for MRD stratiﬁcation
736 identiﬁed before 
        August, 2009
323 identiﬁed after 
         August, 2009
Figure 2: Trial proﬁ le
MRD=minimal residual disease. *One patient had Burkitt’s lymphoma, one T-cell lymphoma, one T non-Hodgkin 
lymphoma, one mature B-cell acute lymphoblastic leukaemia, two acute myeloid leukaemia, ﬁ ve mixed-phenotype 
acute leukaemia, and one precursor B non-Hodgkin lymphoma. †Results not reported here; longer follow-up 
necessary. ‡No patients lost to follow-up before 1 year or excluded from analysis. 
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regression multivariate analyses to test whether eﬀ ects 
of prognostic factors were independent, with additional 
interaction tests and tests of proportional hazards using 
an interaction with time variable for signiﬁ cant factors. 
All analyses were by intention to treat and p values two-
sided. We did statistical analyses in SAS (version 9.2) 
or in-house programs. We created all ﬁ gures with 
R (version 2.15.1).
The chief investigator (AV) did a detailed review of 
individual treatment-related deaths to attribute causal 
association with phase of treatment. The analyses of 
treatment-related deaths are based on this detailed 
review, whereas numbers used for the survival analyses 
are not to allow comparison with previous trials. 
This trial is registered, number ISRCTN07355119.
Role of the funding source 
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Of 3207 patients registered in the trial (ﬁ gure 2), 59 were 
Philadelphia chromosome positive: 52 were transferred to 
EsPhALL and seven to UKALL XII. Initial stratiﬁ cation 
resulted in 1816 NCI standard-risk and 1310 NCI high-risk 
patients. On the basis of cytogenetics and early bone-
marrow response, 1732 patients were reclassiﬁ ed as 
clinical standard risk, 989 clinical intermediate risk, and 
405 clinical high risk (ﬁ gure 2). All eligible trial patients, 
with the exception of those who died within 35 days or 
never achieved remission (n=34), were tested for MRD 
status after induction and before ﬁ rst interim 
maintenance, but clinical high-risk patients were not 
eligible for MRD stratiﬁ cation and randomisation. MRD 
status was low risk in 1090 (35%) of 3092 patients tested 
for MRD status, high risk in 1030 (33%), and indeterminate 
risk in 972 (31%). A further seven patients who failed 
induction treatment were also recorded as MRD high risk.
The proportion of patients who could not be classiﬁ ed 
on the basis of MRD (indeterminate group) decreased 
with time because of improvements in sample quality 
(599 [38%] of 1591 in 2003–07; 373 [25%] of 1501 in 
Trial overall 
(n=3126)
MRD low risk Eligible but not 
randomised 
(n=215)
Underwent MRD low-risk randomisation p value*
Total (n=1059) Eligible for 
randomisation 
(n=736)
One delayed 
intensiﬁ cation 
(n=260)
Two delayed 
intensiﬁ cations 
(n=261)
Total (n=521)
Sex
Male 1776 (57%) 593 (56%) 415 (56%) 115 (53%) 142 (55%) 158 (61%) 300 (58%) 0·31
Female 1350 (43%) 466 (44%) 321 (44%) 100 (47%) 118 (45%) 103 (39%) 221 (42%) ··
Age (years)
Median (IQR) 5 (3–10) 4 (3–8) 4 (3–8) 5 (3–9) 4 (3–8) 4 (3–8) 4 (3–8) 0·79
<2 210 (7%) 62 (6%) 42 (6%) 13 (6%) 13 (5%) 16 (6%) 29 (6%) 0·61†
2–9 2077 (66%) 764 (72%) 534 (73%) 153 (71%) 192 (74%) 189 (72%) 381 (73%) ··
10–15 610 (20%) 179 (17%) 127 (17%) 36 (17%) 46 (18%) 45 (17%) 91 (17%) ··
≥16 229 (7%) 54 (5%) 33 (4%) 13 (6%) 9 (3%) 11 (4%) 20 (4%) ··
Immunophenotype
B lineage 2733 (87%) 978 (92%) 680 (92%) 194 (90%) 241 (93%) 245 (94%) 486 (93%) 0·16
T lineage 386 (12%) 81 (8%) 56 (8%) 21 (10%) 19 (7%) 16 (6%) 35 (7%) ··
Not known 7 (<1%) 0 0 0 0 0 0 ··
National Cancer Institute risk group
High‡ 1310 (42%) 386 (37%) 263 (36%) 84 (39%) 85 (33%) 94 (36%) 179 (34%) 0·23
Standard§ 1816 (58%) 673 (64%) 473 (64%) 131 (61%) 175 (67%) 167 (64%) 342 (66%) ··
White blood cell count (×109 per L)
Median (IQR) 12 (5–40) 11 (5–34) 11 (5–31) 12 (5–36) 10 (4–30) 9 (5–28) 10 (5–28) 0·19
<10 1407 (45%) 494 (47%) 360 (49%) 99 (46%) 127 (49%) 134 (51%) 261 (50%) 0·56¶
10–19 502 (16%) 177 (17%) 128 (17%) 38 (18%) 44 (17%) 46 (18%) 90 (17%) ··
20–49 526 (17%) 184 (17%) 113 (15%) 32 (15%) 45 (17%) 36 (14%) 81 (16%) ··
50–99 315 (10%) 119 (11%) 75 (10%) 28 (13%) 24 (9%) 23 (9%) 47 (9%) ··
≥100 376 (12%) 85 (8%) 60 (8%) 18 (8%) 20 (8%) 22 (8%) 42 (8%) ··
Data are n (%), unless otherwise stated.*Comparing eligible MRD low risk who were and were not randomised. †p for trend (age groups as ordered categories)=0·51. ‡Patients in this group who were MRD low 
risk were clinical intermediate risk. §Patients in this group who were MRD low risk were clinical standard risk. ¶p for trend=0·13. 
Table 1: Baseline characteristics in the trial overall
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2008–11). The proportion of patients with an informative 
MRD result who were MRD low risk or high risk varied 
by age, white blood cell count, and immunophenotype 
(data not shown). 
Of 736 eligible MRD low-risk patients, 521 underwent 
randomisation (ﬁ gure 2). We recorded no diﬀ erence in 
the characteristics of MRD low-risk patients who did and 
did not undergo randomisation (table 1). Follow-up 
continued to Oct 31, 2011, with a median follow-up of 
46 months (IQR 25–70) for the trial overall and 57 months 
(42–72) for patients who underwent low-risk 
randomisation, because this randomisation ceased 
2 years before the high-risk randomisation. The results of 
the high-risk randomisation will be reported elsewhere 
once there has been suﬃ  cient time for follow-up.
Of the 3126 patients who were eligible for analyses in the 
trial overall, a small proportion experienced any event or 
died in the ﬁ rst 6 years of follow-up. 5-year EFS was 87·2% 
(95% CI 85·8–88·6) and 5-year overall survival was 91·5% 
(95% CI 90·3–92·7). The 5-year cumulative risk of relapse 
was 8·8% (95% CI 7·6–10·0; ﬁ gure 3, table 2). The risk of 
bone-marrow relapse was higher than for non-bone-
marrow relapse, any CNS relapse, and isolated CNS 
relapse (table 2). The risk of isolated CNS relapse was 
1·8% (95% CI 1·2–2·4) for patients with B-lineage ALL 
and 3·2% (1·2–5·2) for those with T-lineage ALL. The only 
subgroup with a fairly high risk of isolated CNS relapse 
was patients with T-lineage ALL and a white blood cell 
count of greater than 200 × 10⁹ per L (12·1%, 95% CI 
0·5–23·7), but only four CNS events occurred in 55 such 
patients. Secondary tumours occurred in 16 patients (ﬁ ve 
had acute myeloid leukaemia [one post-relapse], one 
myelodysplasia, two second ALL, one T-cell lymphoma, 
one neuroblastoma, two histiocytic sarcoma, one Epstein–
Barr virus lymphoma, one Ewing’s sarcoma, one 
lymphoblastic lymphoma, and one low-grade glioma), of 
whom eight died. Of the 47 patients who received an 
allogeneic haemopoietic stem-cell transplantation, 
30 (64%) were alive and relapse free as of Oct 31, 2011.
Analysis of outcome by leukaemia cytogenetics is in 
progress and will be reported separately. Of other 
prognostic factors, MRD risk status was the single most 
important determinant of outcome (appendix), with a 
5-year cumulative relapse rate of 4·0% (95% CI 2·4–5.6) 
in MRD low-risk patients versus 15·0% (12·3–17·7) in 
high-risk patients (log-rank p<0·0001). Older age, high 
white blood cell count, and T-cell immunophenotype were 
signiﬁ cantly associated with MRD high-risk status (data 
not shown). With exclusion of MRD indeterminate 
patients, 106 (81%) of 131 relapses occurred within the 
MRD high-risk group. Multivariate Cox analyses showed 
that age, white blood cell count, and MRD risk group were 
independently associated with relapse-free survival 
(table 3, appendix). In Cox analyses, the eﬀ ects of age 
(pinteraction=0·01) and white blood cell count (pinteraction=0·001), 
but not MRD (pinteraction=0·09), varied signiﬁ cantly during 
follow-up. With a restriction to 2 years, MRD (HR 5·82, 
95% CI 2·62–12·91; p<0·0001), age (1·13, 1·08–1·18; 
p<0·0001), and the logarithm of white blood cell count 
(1·45, 1·24–1·70; p<0·0001) all aﬀ ected relapse-free 
survival. After 2 years, only MRD was signiﬁ cant (3·36, 
1·97–5·73; p<0·0001), although more follow-up is needed.
We recorded no diﬀ erence in EFS or relapse risk 
between MRD low-risk patients whose MRD had become 
undetectable at day 29 and those with less than 0·01% 
MRD at day 29 but became undetectable by week 11. 
Additionally, we noted no diﬀ erence between patients 
with undetectable MRD and those with less than 0·005% 
MRD at day 29. 
We noted an interaction between MRD risk status and 
NCI risk for EFS (p=0·04). Within the MRD high-risk 
group, 5-year EFS was lower in NCI high-risk patients 
(72·8%, 95% CI 67·9–77·7) than in NCI standard-risk 
patients (85·8%, 82·1–89·5; p<0·0001; appendix). 
On the basis of review by the chief investigator, 
17 deaths were classiﬁ ed as having been caused by 
Number 
of events
Actuarial percentage at 
5 years (95% CI)
Induction failure 34 1·1% (0·7–1·5)
Isolated CNS relapse 44 1·9% (1·3–2·5)
Any CNS relapse 69 3·0% (2·2–3·8)
Non-CNS relapse 123 5·9% (4·7–7·1)
Any bone marrow relapse 140 6·6% (5·4–7·8)
Non-bone marrow relapse 52 2·3% (1·7–2·9)
Relapse 192 8·8% (7·6–10·0)
Secondary tumour 15 0·6% (0·2–1·0)
Death in remission* 77 2·7% (2·1–3·3)
Any event 318 87·2% (85·8–88·6)†
Death 224 91·5% (90·3–92·7)†
With censoring at competing events. *Excludes patients who died after 
development of a secondary tumour. †Event-free percentage. 
Table 2: Kaplan-Meier estimates for speciﬁ c events at 5 years
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Figure 3: Event-free survival, relapse, and overall survival in the trial overall
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induction therapy despite having occurred after day 35, 
because the onset of the causative event was before that 
timepoint. Most treatment-related deaths were due to 
infection (table 4). 34 (2%) of 1578 patients who received 
four drugs during induction (clinical intermediate or 
high risk) died compared with 12 (1%) of 1548 patients 
who received three drugs (clinical standard risk; 
p=0·001). The number of deaths in remission did not 
diﬀ er by clinical risk group (21 [1%] of 1536 standard-risk 
patients, 19 [2%] of 885 intermediate-risk patients, and 
11 [1%] of 659 high-risk patients; p=0·35). 
Clinical high-risk patients experienced more toxic 
eﬀ ects that were attributable to asparaginase 
(hypersensitivity and pancreatitis) as a result of higher 
cumulative doses of asparaginase than did standard-risk 
and intermediate-risk patients (table 5, appendix). 
Encephalopathy was more frequent in patients aged at 
least 10 years (116 [14%] of 839) than in those younger 
than 10 years (129 [6%] of 2287; p<0·0001), as was 
osteonecrosis (100 [12%] vs 15 [1%]; p<0·0001), infection 
(168 [20%] vs 322 [14%]; p<0·0001), any thrombosis 
(41 [5%] vs 44 [2%]; p<0·0001), CNS thrombosis (28 [3%] 
vs 22 [1%]; p<0·0001), and mucositis (26 [3%] vs 15 [1%]; 
p<0·0001).
In the population of MRD low-risk patients who 
underwent randomisation, we recorded no diﬀ erence in 
EFS, overall survival, or relapse risk between standard or 
reduced treatment groups (ﬁ gure 4, table 6). 5-year EFS 
was 94·4% (95% CI 91·1–97·7) with one course of delayed 
treatment and 95·5% (92·8–98·2) with two courses. The 
diﬀ erence in 5-year EFS was 1·1% (95% CI –5·6 to 2·5), 
which means the primary endpoint of the randomisation 
(to rule out a 7% reduction in EFS) was achieved. 5-year 
overall survival in the group given one delayed 
intensiﬁ cation (97·9%, 95% CI 95·7–100·0) and that 
given two delayed intensiﬁ cations (98·5%, 96·9–100·0) 
did not diﬀ er signiﬁ cantly (OR 0·67, 95% CI 0·19–2·30; 
p=0·53). In the group given standard treatment, six of 261 
patients relapsed (two isolated marrow, one isolated CNS, 
two combined marrow and CNS, and one combined 
marrow and skin), two had secondary tumours (one acute 
myeloid leukaemia and one lymphoblastic lymphoma), 
and three died in remission (one because of respiratory 
syncytial virus pneumonitis during maintenance 
treatment [patient with Down’s syndrome], one veno-
occlusive disease and herpes simplex virus pneumonitis 
with pulmonary haemorrhage in the second course of 
delayed intensiﬁ cation, and one Gram-negative sepsis in 
the ﬁ rst course of delayed intensiﬁ cation; table 6). In the 
reduced-treatment group, 11 of 260 patients relapsed 
(three isolated marrow, four isolated CNS, two combined 
marrow and CNS, one testes, and one isolated cervical 
lymph node). No patients in the reduced-treatment group 
died in remission. The numbers of deaths in remission, 
serious adverse events, and Common Terminology 
Univariate log rank* Univariate Cox regression* Multivariate (Cox regression)†
Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value Hazard ratio (95% CI) p value
Sex (female vs male) 0·65 (0·49–0·86) 0·003 0·64 (0·47–0·86) 0·003 0·78 (0·54–1·13) 0·18
Age‡ 1·84 (1·48–2·30) <0·0001 1·09 (1·06–1·11) <0·0001 1·10 (1·05–1·15) <0·0001
White blood cell count§ 1·36 (1·22–1·50) <0·0001 1·32 (1·20–1·45) <0·0001 1·35 (1·17–1·56) <0·0001
MRD risk (high vs low) 3·83 (2·72–5·39) <0·0001 4·69 (3·04–7·26) <0·0001 4·02 (2·59–6·25) <0·0001
NCI risk group (high vs standard) 2·06 (1·54–2·75) <0·0001 2·01 (1·51–2·68) <0·0001 0·83 (0·49–1·40) 0·48
Immunophenotype (T vs B) 2·47 (1·58–3·84) 0·0002 2·01 (1·42– 2·85) <0·0001 0·61 (0·34–1·02) 0·06
MRD=minimal residual disease. NCI=National Cancer Institute. *Univariate analysis includes all available patients except MRD indeterminate patients in analyses of MRD risk. 
†Multivariate analysis presents a ﬁ nal model that includes MRD risk group, and is therefore based on a reduced number of patients. ‡Age as a continuous variable in Cox 
analyses, with groups of <2 years, 2–9 years, 10–15 years, and 16 years or older. §Logarithm of white blood cell count as a continuous variable in Cox analyses, with groups of 
<10×10⁹ per L, 10–19×10⁹ per L, 20–49×10⁹ per L , 50–99×10⁹ per L, ≥100×10⁹ per L.
Table 3: Prognostic factors for relapse-free survival in the trial overall
Induction 
(n=3126)
Remission (n=3080)
On protocol Oﬀ  protocol
Total 46 (1%) 51 (2%) 17 (<1%)
Infection 35 (1%) 39 (1%) ··
Bacterial infection 19 (1%) 22 (1%) ··
Fungal infection 9 (<1%) 6 (<1%) ··
Viral infection 2 (<1%) 7 (<1%) ··
Unknown infection 5 (<1%) 4 (<1%) ··
CNS thrombosis 1 (<1%) 1 (<1%) ··
Encephalopathy 1 (<1%) 2 (<1%) ··
Colitis 4 (<1%) 0 ··
Steroid toxicity 2 (<1%) 1 (<1%) ··
Pancreatitis 0 1 (<1%) ··
SIADH 0 1 (<1%) ··
Other 3 (<1%) 5 (<1%) ··
After stem-cell 
transplantation
·· ·· 10 (<1%)
Secondary malignancy ·· ·· 5 (<1%)*
Unknown ·· 1 (<1%) 2 (<1%)
SIADH=syndrome of inappropriate antidiuretic hormone secretion. *Two 
myelodysplasia, one T non-Hodgkin lymphoma, one glioblastoma multiforme, 
and one neuroblastoma.
Table 4: Treatment-related deaths 
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Criteria for Adverse Events grade 3 or 4 toxic eﬀ ects in 
patients given reduced treatment and those given 
standard treatment did not diﬀ er signiﬁ cantly (table 7). 
However, the second delayed intensiﬁ cation course was 
associated with one (<1%) treatment-related death and 
74 episodes of grade 3 or 4 toxic eﬀ ects in 45 patients 
(17%) given standard treatment, of whom 21 had at least 
one grade 3 or 4 infection.
347 MRD low-risk patients were registered after closure 
of the low-risk randomisation in August, 2009 (ﬁ gure 2). 
They received one course of delayed intensiﬁ cation. The 
outcome for these patients is included in that reported 
for the overall MRD low-risk group (appendix), because 
their follow-up is too short to be analysed separately. 
Discussion
The results of our trial show that a reduction of post-
remission treatment is feasible for children and young 
adults with ALL predicted to have a low risk of relapse on 
the basis of rapid clearance of MRD by the end of 
induction therapy. We have reported a 5-year EFS in the 
trial overall that is comparable with the benchmark of 
85·6% established in a study of 498 patients.8 A reduction 
in relapse risk in this study has resulted in a 7·2% 
improvement in 5-year EFS compared with our previous 
trial (UKALL 99),1 in which only patients aged 18 years or 
younger were recruited. Combined with a signiﬁ cant 
reduction in treatment-related mortality, the improved 
EFS resulted in a 4% improvement in 5-year overall 
survival to 92·3% for that age group compared with 
UKALL 99.16 Although the improvement was recorded in 
all risk groups, higher-risk patients beneﬁ ted the most, 
with a 12% improvement in 5-year EFS for NCI high-risk 
patients and an 11·5% improvement in patients with 
T-lineage ALL,16 leading to a signiﬁ cant increase in overall 
survival for these groups compared with UKALL 99.1 The 
low frequency of isolated and any CNS relapse within 
5 years is reassuring, and was equivalent to that reported 
in studies2,3 in which a signiﬁ cantly higher proportion of 
patients received cranial irradiation than in our trial. 
Restricted use of cranial radiotherapy combined with a 
small proportion of patients who received an allogeneic 
haemopoietic stem-cell transplantation relative to other 
trials and the absence of etoposide from our treatment 
Total (n=3126) Clinical standard 
risk (n=1548)
Clinical intermediate 
risk (n=909)
Clinical high 
risk (n=669)
p value for 
standard risk vs 
intermediate risk
p value for standard/
intermediate risk vs 
high risk
Any serious adverse event 1101 (35%) 369 (24%) 434 (48%) 298 (45%) <0·0001 <0·0001
Any infection 490 (16%) 191 (12%) 192 (21%) 107 (16%) <0·0001 0·80
Fungal infection 110 (4%) 35 (2%) 51 (6%) 24 (3%) <0·0001 0·91
Seizure 135 (4%) 38 (2%) 46 (5%) 51 (8%) 0·001 <0·0001
Other encephalopathy 110 (4%) 21 (1%) 64 (7%) 25 (4%) <0·0001 0·73
Asparaginase hypersensitivity 54 (2%) 3 (<1%) 8 (1%) 43 (6%) 0·11 <0·0001
Pancreatitis 50 (2%) 10 (1%) 18 (2%) 22 (3%) 0·003 <0·0001
Avascular necrosis 115 (4%) 8 (1%) 80 (9%) 27 (4%) <0·0001 0·58
Any thrombosis 85 (3%) 27 (2%) 37 (4%) 21 (3%) 0·0005 0·45
CNS thrombosis 50 (2%) 17 (1%) 22 (2%) 11 (2%) 0·01 0·92
Colitis 47 (2%) 22 (1%) 17 (2%) 8 (1%) 0·39 0·46
Vincristine neurotoxicity 65 (2%) 26 (2%) 22 (2%) 17 (3%) 0·20 0·35
SIADH 11 (<1%) 3 (<1%) 4 (<1%) 4 (1%) 0·227 0·23
Mucositis 41 (1%) 6 (<1%) 8 (1%) 27 (4%) 0·12 <0·0001
Other serious adverse event 280 (9%) 82 (5%) 123 (14%) 75 (11%) <0·0001 0·02
Some patients had more than one type of event. SIADH=syndrome of inappropriate antidiuretic hormone secretion.
Table 5: Number of speciﬁ c toxic eﬀ ects by clinical risk groups
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Figure 4: Event-free survival and relapse in MRD low-risk patients
MRD=minimal residual disease.
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regimens should hopefully reduce the risk of treatment-
related cancers.17,18 
The overall outcomes reported here and in other recent 
trials19,20 have been obtained even though no new drugs for 
treatment of ALL have been introduced in the past 
30 years; targeted drugs, such as monoclonal antibodies 
and protein kinase inhibitors, were not available for 
testing when our trial opened. Without a randomised or 
case-matched comparison, we cannot be certain of the 
reasons for the improvement in outcome. The randomised 
interventions in the trial are unlikely to provide the 
explanation, because less than half the patients underwent 
randomisation. The use of dexamethasone and pegylated 
asparaginase throughout treatment was probably an 
important contributor. Several large randomised clinical 
trials have shown that dexamethasone has a better eﬃ  cacy 
in prevention of systemic and CNS relapse than does 
prednisolone.21–23 Pegylated asparaginase has better 
pharmacokinetic24,25 and pharmacodynamic properties,26 
and a lower risk of hypersensitivity reactions on re-
exposure27 than does the native formulation. 
The non-relapse mortality in induction and in remission 
is conspicuous when considered in the context of low 
relapse risk. Deaths caused by toxic eﬀ ects amount to half 
the deaths reported in our trial so far, although the 
proportion will diminish with longer follow-up as more 
patients relapse. Dexamethasone is more toxic than is 
prednisolone and is probably an important contributor to 
the risk of serious bacterial and fungal infection. In a 
recently concluded European study, AIEOP-BFM 2000,23 
twice as many patients in the group given dexamethasone 
died during induction than in the group given 
prednisolone; other studies28,29 have had similar results. 
Additionally, dexamethasone might be associated with a 
higher risk of osteonecrosis than is prednisolone,29 but that 
has not been a universal experience.22,30 Dexamethasone 
aﬀ ects quality of life more than prednisolone does,31 
although the eﬀ ect does not persist in the long term.32 
Dose, scheduling, and interaction with anthracyclines are 
important determinants of the risk of steroid-associated 
toxic eﬀ ects, and we are testing novel schedules of 
dexamethasone in our next trial in an attempt to reduce 
the toxic eﬀ ects while retaining the eﬃ  cacy of this drug. 
Toxic eﬀ ects attributable to pegylated asparaginase were 
similar to or lower than that reported with the native 
formulation. Most hypersensitivity reactions occurred in 
high-risk patients when re-exposed to the drug during 
consolidation or ﬁ rst interim maintenance course. Studies 
of native Escherichia coli asparaginase26,33 have reported a 
frequency of 20–40% of hypersensitivity reactions 
associated with asparaginase intensiﬁ cation courses.
In view of these toxic eﬀ ects, we were pleased to note 
that treatment reduction is feasible in a substantial 
subgroup of patients with a low risk of relapse (panel). 
MRD stratiﬁ cation identiﬁ ed 40–50% of patients 
(depending on age) who—irrespective of conventional risk 
factors—have a chance of surviving to 5 years relapse free 
of about 95%. We have shown that these patients do not 
require a second intensiﬁ cation course to achieve this 
outcome, thus avoiding exposure to acute toxic eﬀ ects. 
Whether they also have decreased risk of late cardiac toxic 
eﬀ ects and secondary cancers due to reduced exposure to 
anthracyclines and alkylating agents (appendix) will 
become apparent only after longer follow-up. 
After UKALL 2003 opened, two US trials34,35 also reported 
no beneﬁ t of a second intensiﬁ cation course for NCI 
standard-risk and high-risk patients. However, treatment 
was not stratiﬁ ed by MRD in either trial and the overall 
One delayed intensiﬁ cation 
(n=260)
Two delayed intensiﬁ cations 
(n=261)
Unadjusted analyses Adjusted analyses*
Number of 
events
Actuarial 
percentage at 
5 years (95% CI)
Number of 
events
Actuarial 
percentage at 
5 years (95% CI)
Unadjusted odds ratio 
for group given 
two delayed 
intensiﬁ cations 
(95% CI)
Two-sided 
p value
Adjusted odds 
ratio for group 
given two delayed 
intensiﬁ cations 
(95% CI)
Two-sided 
p value
Any event† 11 5·6% (2·3–8·9) 11 4·5% (1·8–7·2) 1·00 (0·43–2·31) 0·99 1·09 (0·47–2·53) 0·84
Relapse‡ 11 5·6% (2·3–8·9) 6 2·4% (0·2–4·6) 0·55 (0·21–1·43) 0·23 0·60 (0·23–1·57) 0·30
Remission death 0 0% 3 1·2% (0–2·6) 7·40 (0·77–71·04) 0·08 8·39 (0·86–81·61) 0·06
Any death 6 2·1% (0–4·3) 4 1·5% (0–3·1) 0·67 (0·19–2·30) 0·53 0·71 (0·21–2·48) 0·61
MRD=minimal residual disease. *Adjusted for variables upon which randomisation was balanced: age (<10 years vs ≥10 years), sex (males vs female), white blood cell count 
(<50×10⁹ per L vs ≥50×10⁹ per L). †Includes two secondary tumours. ‡Includes relapse in patient who was incorrectly reported as low risk (allocated to receive two delayed 
intensiﬁ cations). 
Table 6: Events in MRD low-risk patients who underwent randomisation
One delayed 
intensiﬁ cation 
(n=260)
Two delayed 
intensiﬁ cations 
(n=261)
Relative risk for group 
given two delayed 
intensiﬁ cations (95% CI)
Two-sided 
p value
Grade 3–4 toxic eﬀ ect* 189 (73%) 200 (77%) 1·05 (0·95–1·16) 0·30
Serious adverse event 70 (27%) 82 (31%) 1·17 (0·89–1·53) 0·26
Cumulative toxicity† 195 (75%) 204 (78%) 1·04 (0·95–1·15) 0·39
MRD=minimal residual disease. *Measured with Common Terminology Criteria for Adverse Events. †Deﬁ ned as 
remission death, grade 3–4 toxic eﬀ ect, or serious adverse event.
Table 7: Toxic eﬀ ects in MRD low-risk patients who underwent randomisation
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intensity of treatment diﬀ ers signiﬁ cantly from our trial. 
The conclusion of the US trials34,35 was that intensiﬁ ed 
interim maintenance with one delayed intensiﬁ cation 
course was the optimum therapy for NCI standard-risk 
and high-risk patients with a rapid morphological early 
response. Our trial has extended the previous ﬁ ndings by 
establishing that molecular MRD monitoring identiﬁ es a 
large group of patients with a rapid morphological early 
response who do not require a second delayed 
intensiﬁ cation course or intensiﬁ ed interim maintenance 
treatment to achieve a high chance of event-free survival 
to 5 years. Additionally, a small proportion of patients can 
be identiﬁ ed as low risk by karyotype and MRD response 
by the Children’s Oncology Group criteria; the remaining 
subgroups can receive more intensive interim 
maintenance and delayed intensiﬁ cation therapy than was 
used in our protocol. An international trial, AIEOP-BFM 
2000,7,14 has also tested treatment reduction and 
intensiﬁ cation interventions for MRD high-risk and 
standard-risk groups, but the results are yet to be reported. 
We note three main limitations of our study: an 
informative MRD result was not available for a third of 
patients enrolled; median follow-up of MRD low-risk 
patients was fairly short; and the reduction in treatment 
achieved by omitting the second delayed intensiﬁ cation 
is fairly modest. We are reasonably conﬁ dent that the 
EFS for MRD low-risk patients will remain stable during 
extended follow-up, because no late relapses in the 
MRD low-risk group have been reported in the BFM 90 
study6 or our retrospective study of ALL (unpublished). 
Improvements in the quality of samples and ability to 
ﬁ nd MRD markers have meant that an informative 
MRD result is available for 92% of patients in our 
successor trial UKALL 2011 (ISRCTN64515327), which 
opened in April, 2012, and is testing ways to further 
reduce risk of treatment-related toxic eﬀ ects. In future, 
new drugs36,37 designed to target leukaemia-speciﬁ c 
receptors and proteins could replace elements of 
conventional chemotherapy regimens that are the cause 
of some of the major toxic eﬀ ects, thereby reducing 
toxicity while retaining overall treatment eﬃ  cacy. 
Finally, translation of advances in understanding of the 
molecular biology of ALL and its eﬀ ect on phenotype 
and clinical outcome38–40 will help to deﬁ ne speciﬁ c 
subgroups that might beneﬁ t from such an approach. 
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